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Background: The Canadian Alliance for Healthy Hearts and Minds (CAHHM) is a pan-Canadian, prospective,
multi-ethnic cohort study being conducted in Canada. The overarching objective of the CAHHM is to understand
the association of socio-environmental and contextual factors (such as societal structure, activity, nutrition, social
and tobacco environments, and access to health services) with cardiovascular risk factors, subclinical vascular
disease, and cardiovascular and other chronic disease outcomes.
Methods/Design: Participants between 35 and 69 years of age are being recruited from existing cohorts and a
new First Nations Cohort to undergo a detailed assessment of health behaviours (including diet and physical
activity), cognitive function, assessment of their local home and workplace environments, and their health services
access and utilization. Physical measures including weight, height, waist/hip circumference, body fat percentage,
and blood pressure are collected. In addition, eligible participants undergo magnetic resonance imaging (MRI) of
the brain, heart, carotid artery and abdomen to detect early subclinical vascular disease and ectopic fat deposition.
Discussion: CAHHM is a prospective cohort study designed to investigate the impact of community level factors,
individual health behaviours, and access to health services, on cognitive function, subclinical vascular disease, fat
distribution, and the development of chronic diseases among adults living in Canada.Background
Cardiac, vascular, and cognitive dysfunction have a
tremendous impact on the quality of life, longevity and
health care costs in Canada, and globally. It is of
paramount importance to understand the early determi-
nants of such dysfunction and its progression to clinical
events, given the increasing prevalence of known cardio-
vascular (CV) risk factors, which result in organ
dysfunction including heart failure, non-alcoholic fatty* Correspondence: anands@mcmaster.ca
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the financial sustainability of health care systems. Car-
diovascular Disease (CVD) is a leading cause of morbid-
ity and mortality in Canada, and places a large burden of
cost on the health care system. Each year approximately
70,000 Canadians die from CV causes and many more
suffer life-threatening CV events such as myocardial
infarction (MI) and stroke [1]. It has been estimated that
cardiovascular diseases cost our health care system $22
billion dollars each year in direct and indirect costs, a
figure that is expected to grow over time [2]. Addition-
ally, CV risk factors account for up to half of the attrib-
utable risk for dementia, mediated in large part byle is distributed under the terms of the Creative Commons Attribution 4.0
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The rapid increase of overweight and obesity among
Canadians and its associated consequences, including
hypertension and diabetes add to the problem. Import-
antly, CVD in Canada increasingly affects women and
individuals from non-white ethnic groups [1, 3]. While
the treatment of clinical events caused by CVD has im-
proved, the effective prevention of CVD with its implica-
tions on well-being and health care costs remains a
challenge, due in part to knowledge gaps regarding the
impact of social and built environments in relation to in-
dividual risk factors and thus on efficient political strat-
egies to reduce CVD burden. Furthermore, there is a
lack of sensitive, early risk markers and thus information
on these relationships before the onset of symptomatic
organ dysfunction is limited. In order to address these
gaps in our knowledge, we convened the Canadian Alliance
for Healthy Hearts and Minds (CAHHM) – a prospective
cohort of men and women recruited through existing
cohorts in Canada and an First Nations cohort.
The specific objectives of the CAHHM are
1) To understand the role of socio-environmental and
contextual factors (such as societal structure, activity,
nutrition, social and tobacco environments, and access
to health services) on CV risk factors, subclinical
disease, and clinical CV events at the individual and
population levels. This includes the impact of contextual
factors on geographic variation in CVD (ie rural vs.
urban, and east to west gradient), and their relative
impact compared to individual level factors.
2) To characterize the unique patterns of contextual
factors as well as acculturation, cultural continuity, and
migration experience as related to individual CV risk
factors, health service utilization (ie screening, access to
diagnostics and treatments), and clinical outcomes
among high risk ethnic groups including South Asian,
Chinese, and African origin, as well as reserve-based
First Nations people from across Canada.
3) To identify early subclinical dysfunction and tissue
abnormalities in the brain, blood vessels and the
heart, to characterize abdominal and pericardial fat
distribution, and to investigate the association of
dysfunction with contextual and individual
determinants. Furthermore, the data will shed light
on the predictive value of novel markers of
subclinical abnormalities and dysfunction on the
development of clinical events related to cardiac,
vascular and cognitive dysfunction.
Methods/Design
CAHHM is a ‘cohort of cohorts’ as the majority of
participants (>80 %) will be recruited through existingcohorts: 1) Canadian Partnership for Tomorrow Project
(CPTP), a harmonized longitudinal population study captur-
ing health data, physical measures and biologics of over
300,000 Canadians (www.partnershipfortomorrow.ca). CPTP
participants provide broad consent to research by internal
and external scientists, and linkage to administrative health
data. CPTP is a federation of five regional cohorts: the BC
Generations Projects, Alberta’s Tomorrow Project, the
Ontario Health Study, CARTaGENE, and Atlantic PATH
(Atlantic Partnership for Tomorrow's Health), 2) the Pro-
spective Urban Rural Evaluation (PURE)-Canada cohort, 3)
the Montreal Heart Institute (MHI) Biobank, and 4) a newly
formed First Nations Cohort study. The details of the separ-
ate cohorts are found in the Additional file 1.
Eligibility and recruitment of participants into CAHHM
Participants are eligible for CAHHM if they were be-
tween ages 35 and 69 years (inclusively) at time of
screening [or for First Nations participants ≥ 18 years]
and willing to undergo an MRI scan and all other re-
quired study procedures. In order to recruit the majority
of participants without existing CVD we asked each co-
hort to include participants of whom less than 20 % have
known CVD, and about 50 % are women, all balanced
across age strata 35–45, 46–55, 56–69 years. Some varia-
tions exist between cohorts given their differences in
feasibility of recruitment and access to MRI centres.
(Table 1) Details on the new First Nations cohort will be
published in a separate manuscript.
Clinical assessment
The clinical assessment for CAHHM participants con-
sisted of: a) completion of questionnaires, b) physical mea-
surements, c) collection of blood samples in some
participants (stored blood samples will be used for others),
and d) a MRI scan of brain, heart, carotid artery and abdo-
men, details of each component are provided below.
Health questionnaires
Personal and Medical History were collected using
standardized questions including family history, and
health behaviors. Diet and physical activity were col-
lected using a food frequency questionnaire (FFQ) and
the short form International Physical activity Ques-
tionnaire (IPAQ). (Table 2)
Cognitive function
Cognitive function measures in CAHHM were selected
balancing the need for a brief, cost effective, and sensi-
tive measure appropriate for use in a 35–69 year age
group. Two assessments were chosen, first the Digit
Symbol Substitution (DSS) test (Wechsler Adult
Intelligence Scale IV version) was chosen because it
displayed age-related effects over the age range of 40–70
Table 1 Participant Selection Criteria for Alliance Recruitment – By Cohort
CARTaGENE OHS BCGP APATH Alberta’s tomorrow
project
PURE MHI First Nations
Preliminary Selection Criteria of Participants
Email Yes Yes Yes NA Yes NA NA NA
Blood Sample
previously collected
Yes – also new
sample
Yes Yes – also new
sample collected




Yes – new sample
for Hamilton only
Yes – also new
sample
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Table 2 List of Measures/Questionnaires of Baseline Visit
Questionnaire/Measure Source Time to
complete (minutes)
Method
Physical Activity IPAQ-S [71] 4 Self Administered
Dietary Intake (Macro and Micro Nutrients) SHARE-FFQ [72] and DHQ II 22 Self Administered
Cognitive Function: Digital Symbol Substitution DSS [73] 5 Administered by RA
Montréal Cognitive Assessment MoCA [9] 8 Administered by RA
Community Factors (Individual Perception) EPOCH-2 [58] 21 Self Administered
Immigrant Questionnaire Longitudinal Survey of Immigrants in Canada [60] 3 Self Administered
Acculturation Vancouver Inventory of Acculturation [61] 3 Self Administered
CVD related Health Services Questionnaire Multi-source: Canadian Community Health Survey,
Ontario Health Study
7 Self Administered
General CVD Questionnaire Prior Longitudinal Studies (SHARE, PURE) 7 Self Administered
CPTP Core Baseline Health and Lifestyle
Questionnaire
CPTP Study [74] 14 Self Administered
Physical Measures (blood pressure and
heart rate via OMRON
cuff, Body Fat & Weight via Tanita BIA)
10 Clinic
RA: Research Assistant
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temporary Canadian-based prospective cohort study of
800 participants with similar entry criteria to the Canad-
ian Alliance for Healthy Hearts and Minds [4]. In the
DSS, the participant transcribes as many coded symbols
as possible within a given time (in this case, two mi-
nutes). Lower scores indicate worse performance. The
DSS is sensitive to change over time [5], is lower in per-
sons with silent brain infarct, is independent of language,
is sensitive to mildly impaired cognition [6], and predicts
clinically important events such as falls and mortality [7,
8]. Second, the Montréal Cognitive Assessment (MoCA)
was used as a global cognitive screening test. The MoCA
takes 10–15 min to administer and briefly evaluates the
following domains: delayed recall, verbal fluency, visuo-
spatial skills, clock drawing, executive functions, calcula-
tion, abstraction, language, orientation, attention and
concentration [9]. The test has a sensitivity of 90 % and
specificity of 87 % to detect mild cognitive impairment
in patients and distinguish them from normal controls
[10]. The MoCA has been validated in memory clinic
settings for diagnosis of mild cognitive impairment or
dementia [9–13]. The MoCA tests domains including
executive function and therefore should be more sensi-
tive to vascular cognitive impairment than the Folstein
Mini mental status examination [14–18], is more sensi-
tive to milder forms of impairment [9, 15, 19] and shows
less ceiling effect [19, 20].
Physical measurements
Participants height, weight, percent body fat using the
Tanita BIA machine, waist circumference, hip circumfer-
ence, resting heart rate, and blood pressure using anautomated OMRON cuff are collected. All measure-
ments are taken using a standardized protocol.
Blood collection
New blood samples are collected from cohorts in which
blood had not previously been collected from their par-
ent cohort. A new blood sample will be collected from
First Nations participants, the Alberta’s Tomorrow Pro-
ject, BC Generations, CARTaGENE, Atlantic PATH,
MHI Biobank, and PURE (Hamilton site only).
Rationale for MRI imaging
Imaging-derived markers can be acquired non-invasively
and include focal tissue, thereby increasing the sensitiv-
ity to detect vascular lesions and tissue pathology with
prognostic impact. Among the available imaging tools,
MR imaging combines an outstanding safety profile with
excellent accuracy and reproducibility. Its advantages
also include a high spatial resolution, a small observer
dependence, and excellent. Moreover, it allows for a com-
prehensive, multi-target approach including morphology,
mass, function, flow, vessel lumen, tissue composition,
and metabolism. It can be considered the most efficient
imaging tool for clinical or cohort studies in healthy indi-
viduals. Several existing and conceptualized population-
based cohorts utilize either cardiac or brain MRI, includ-
ing the UK BioBank [21], The German National Cohort
study [22], the Dallas Heart Study [23] the MESA
study [24], Age, Gene/Environment Susceptibility –Rey-
kjavik Study [25, 26], Framingham study [27, 28] and Rot-
terdam study [29, 30]. However, few studies have
comprehensively assessed the cardiovascular system
using MRI, including arterial imaging. In CAHHM,
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ination of the brain, heart, carotid artery and abdo-
men (for visceral and liver adiposity). Of note, the
CAHHM not only uses markers with demonstrated
value, but also novel candidates related to coronary
plaque stability and microvascular function.
MRI Protocol
Details of the CAHHMMRI protocol are found in Tables 3
and 4. The protocol was developed in collaboration with a
multi-disciplinary expert group (see working groups listed
at the end of the conclusion section) balancing the scien-
tific objectives with time efficiency. The protocol uses vali-














LV end-systolic volume index
LV mass-to-volume ratio
LA size and function
RV volume and global
function
Brain
3D T1w MPRAGE 8 Brain Volume










1 Liver fat %
Cerebrovascular
3D T1w MPRAGE 6 Plaque volume and
intraplaque hemorrhage
detection
TOF 6 Plaque volume and
intraplaque hemorrhage
detection
Additional time for positioning
Coil Positioning 6
Total time 42a
aNote this varies depending on: Scanner make and model, hardware and
software used for scanning, need for switching MR coils, participants heart
rate, and MRI technologist experience
Circumferential strain
RV volume and global
function
Phase-contrast cine 4 Aortic elasticity
LGE 12 Myocardial fibrosis
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4 Presence of microbleeds
2D resting state fMRI 4 Functional connectivity
3D arterial spin labeling
(ASL)
7 Cerebral blood flow
2D diffusion tensor
imaging (DTI)




2 Visceral fat area
Liver 2D multi-echo
gradient-echo sequence
1 Liver fat %
Cerebrovascular
3D T1w MPRAGE 8 Plaque volume and
intraplaque hemorrhage
detection
TOF 6 Plaque volume and
intraplaque hemorrhage
detection
3D T1w MPRAGE +
contrast
5 Lipid core, calcification
inflammation/angiogenesis
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tive data are measured or calculated wherever possible. Aside
from established parameters, novel markers are included,
with most of them being acquired by additional images as
part of an extended protocol, performed with the MR con-
trast agent gadobutrol.
Cardiac dysfunction
Cardiac MR (CMR) will provide data on global and re-
gional left ventricular and right ventricular function. This
rationale is based on data from the MESA cohort with its
multi-ethnic population-based sample of 4510 individuals
(mean age 61y), where a 25.6 % prevalence of regional wall
motion abnormalities (RWMA), with a 2.6 % heart failure
rate (vs. 1.0 % in individuals without RWMA) was ob-
served [31]. With its obvious potential as a predictor for
heart failure, the correlation of RWMA with other risk
markers and especially environmental factors becomes an
important target for preclinical research. Its standardized
acquisition [32, 33], high prevalence in the general popula-
tion and strong predictive value for subsequent heart
failure render CMR-derived RWMA an excellent early
marker and primary endpoint in CAHHM. Other markers
include myocardial scarring [34, 35], and coronary vascu-
lar function [36–38]. Furthermore, this is an unprece-
dented opportunity to acquire multi-ethnic normal values
for numerous quantitative cardiac markers. Because of its
outstanding safety profile, standardized approaches, accur-
acy, reproducibility and comprehensive multi-parametric
protocols, we considered CMR the most useful tool for
detecting subtle, early and local changes which may
precede cardiac, vascular and cognitive dysfunction.
Covert stroke and cognitive dysfunction
Recent population-based studies have shown that the preva-
lence of unrecognized “covert” brain infarcts is as high as
30–40 % in the elderly/geriatric population, and current evi-
dence is sufficient to document that covert strokes and is-
chemic white matter damage in the elderly are associated
with cognitive impairments despite the lack of association
with specific symptoms, and are highly predictive of future
stroke and dementia. However, important gaps in knowledge
include the prevalence of brain infarcts prior to age 60 (as
previous studies have focused on the elderly), the predictive
power of covert stroke and ischemic white matter damage
as a marker of important CV events in addition to future
stroke (such as myocardial infarction), and the relationship
between covert stroke and subclinical manifestations of
CVD in other organs. Additionally, both covert stroke and
ischemic white matter damage are partly heritable but the
genetic basis of this risk has not been well defined yet.
Emerging evidence suggests that alterations in brain
structure and function accrue years before clinical symp-
toms of stroke or cognitive dysfunction. In Alzheimer’sdisease, regional brain atrophy and altered glucose me-
tabolism can be detected on neuroimaging 15 years be-
fore the onset of symptoms [39]. By contrast, the
changes in brain structure and function associated with
CV and cerebrovascular disease are largely unknown,
because previous population-based studies used last-
generation MRI technology without high resolution im-
aging. We expect that changes in brain structure (eg as
measured by volumetric brain MRI) and brain func-
tional and structural connectivity (eg as measured by
resting state functional MRI and diffusion tensor im-
aging of white matter tracts) can be detected in associ-
ation with CVD such as hypertension and diabetes,
both in the presence and absence of MRI-visible signs
of irreversible ischemic damage (that is, covert stroke
and ischemic white matter damage). This hypothesis
will be addressed in the Alliance for Healthy Hearts and
Minds, in which high-resolution brain MRI imaging
and a comprehensive assessment of CV risk are
collected.
Carotid atherosclerosis
Subclinical atherosclerosis detected through imaging
of the carotid arteries can provide insights into the
type and burden of atherosclerotic disease. Prior stud-
ies have shown that the carotid vascular bed also acts
as a good representative of vascular disease through-
out the body providing a ‘vascular phenotype’ for the
individual [40]. A variety of imaging techniques are
available for carotid artery imaging, for instance Ultra-
sound generated intimal medial thickness (IMT) and
3D ultrasound. These two sequences will provide
quantitative data regarding luminal narrowing and
vessel wall volume to detect carotid plaque. In
addition, the vessel wall imaging is able to characterize
plaques as high or low risk by detecting the presence
or absence of plaque hemorrhage [41]. Among the
subset of participants undergoing the extended scan in
which intravenous gadolinium is administered plaques
can be further characterized for the presence of lipid
within the plaques.
Measuring ectopic fat deposition in CAHHM
Although several imaging studies have documented
significant associations between measures of ectopic fat
accumulation (including visceral adiposity), cardiometa-
bolic risk markers and clinical outcomes, most of these
large cohort studies (Framingham [42–48], Jackson
Heart Study [49–51], MESA [52, 53], INSPIRE ME IAA
[54], CARDIA [55, 56]) have used computed tomography
to quantify abdominal subcutaneous and visceral adiposity
as well as the accumulation of unwanted lipid deposition
in normally lean tissues such as the heart, the liver, the
pancreas and perivascular adipose tissue. Furthermore,














BC 190 190 (+50) 112904
AB 153 153 (+46) 40 (21.1 %) 76924
SK 49 49 (+8) 21541
MN 66 66 (+12) 23943
ON 526 526 (+208) 282123
QC 419 419 (+108) 55 (10.4 %) 215565
Atlantic 230 230 (+72) 92809
NS 77 77 (+26) 28171
NB 111 111 (+30) 59530
PEI 7 7 (+2) 3995
N/L 35 35 (+14) 1113
*For FSA with income discrepancies across postal codes within the FSA, 2
audits were done to reflect the 25th percentile an
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the Chengdu Study and the NEO Study, most of them
have been limited in scope and do not cover the compre-
hensive spectrum of outcomes considered in CAHHM.
The present study will therefore be one of the most com-
prehensive cardiometabolic MRI studies ever conducted
and will provide a unique opportunity to decipher the re-
spective contributions of specific ectopic fat depots to a
plethora of clinical conditions, going way beyond various
cardiovascular outcomes including particular attention to
several indices of brain function and health. Furthermore,
the substantial subgroup of First Nations people will gen-
erate very much needed data for that population for
whom we do not currently have adequate imaging data to
properly describe to what extent they are susceptible or
not to ectopic fat deposition.
Contextual factors measured at the individual and
community level
Data describing contextual factors that characterize the
nutrition, physical and tobacco environments of commu-
nities from which participants are recruited as well as in-
dividual behaviors in these domains are collected using
the modified EPOCH-1 and modified EPOCH-2 ques-
tionnaires modified from the PURE study [57, 58].
EPOCH-1 is a standardized community audit developed
and validated in the PURE study [57] and EPOCH-2
captures individual’s perceptions of their food, activity,
and tobacco environment also developed in the PURE
study [58] with added questions on social ties, alcohol
use, and workplace activity and food choices and
behaviors.
Community audits
To study community level contextual factors as related
to individual risk factors and clinical events we retro-
spectively defined “community” as participants are
already recruited. After review of the communities from
which participants in the 5 CPTP cohorts and the 2
partner cohorts originate, the forward sortation areas
(FSA) was deemed to be the optimal community unit.
(Table 5) We have chosen the FSA as our definition of
community because: 1) there was low representation of
cohort participants from census tracts in rural areas and
eastern provinces of Canada, 2) the FSA are those re-
ported by census respondents for their place of residence
and this information collected from the census is avail-
able in aggregate for each FSA. This census information
includes age, sex, marital status, families and household
information, housing costs, mobility and migration, im-
migration and citizenship, income and earnings, and eth-
nic groups. This is balanced by some limitations of this
approach include: for certain highly populated urban
areas the FSA is too large to well represent thecommunity—in this scenario, we surveyed multiple pos-
tal codes within the FSA to capture the diversity. The
community level information will be used together with
self-reported perception of community environment as
well as behavior patterns, ie shopping, activity, and
workplace. These will be used together with objective
measures of the built environment from publically avail-
able databases (ie streetsmart walk-score at www.walks-
core.com), which provides information by postal code
on neighborhood walkability, land use mix, transporta-
tion availability and location of food retail outlets [59].
Social capital and social ties
A series of validated questions were used to measure
social support from the family and the wider social en-
vironment and included questions such as participa-
tion in community organizations, civic engagement,
perceived social standing, and intensity of social rela-
tionships with close confidants, and type of contact
with confidants (ie in-person, telephone, email, Face-
book, text messages).
Culture and immigration
Among immigrants to Canada we will probe the reasons
for immigration (economic, family, refugee) and the
socio-cultural connections they have made since immi-
gration using the Immigration Questionnaire [60] and
the Vancouver Inventory of Acculturation [61]. This infor-
mation will be used along with measures of socioeco-
nomic status (education, household income, employment
and marriage) which has already been collected in each of
the participating cohorts.
Table 6 Health system quality indicators
Health system quality indicators measurable from the CPTP CVD Survey
Participants with a family doctor
Difficulties accessing primary or specialist care
Weight assessment by a health professional
Screening for hypertension, diabetes, hyperlipidemia
Diabetics who have had eyes examined by an ophthalmologist, feet
examined, urine protein tested
Smokers who have been offered smoking cessation counseling and/or
stop smoking aids
Hypertensives who have their blood pressure treated and controlled
Participants with hyperlipidemia who have been treated with
medication to control their blood cholesterol levels
Participants with atrial fibrillation who have been treated with blood
thinners
Health system indicators measurable from administrative data
A. Structural variables
# of family doctors/specialists per capita
#, costs and types of ambulatory care visits
#, costs and types of hospitalizations
B. Processes of Care
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A health services questionnaire was developed to collect
information at the individual level and will be supple-
mented by record linkage to administrative, laboratory
and clinical databases available in various Canadian
provinces. With these data sources we plan to analyze
existing population-based databases to create unique
community-level profiles of access and quality of health
care services including the rates of selected CV related
diagnostic tests and treatments. This will be a unique
component of this initiative because health care services
have not been a focus of most traditional cohort studies
to date and yet, it is increasingly recognized that quality
of health care provided to individuals can play a major
role in determining their likelihood of suffering and sur-
viving clinical events [62]. Furthermore, how Canadians
with CV risk factors are managed likely varies across
the country due to factors such as physician and allied
health care personnel availability, type and nature of
primary care services, patient education, and socioeco-
nomic status.
Inclusion criteria
CV and non-CV medications (statins, ACE inhibitors, diuretics, Beta-blockers)
Laboratory screening rates (lipids, diabetes)
Lab results (lipids, diabetes)
ECG, Stress Test, Echo, CT scans, MRI scans
Cardiac Catheterization1. Participants between ages 35 and 69 y (inclusively)
at time of screening
2. Provision of Informed Consent





Myocardial Infarction (STEMI/NSTEMI, unstable angina)
Congestive Heart Failure
Stroke (Ischemic/Hemorrhagic/TIA)
Death (including cause of death)
Atrial Fibrillation
Diabetes and Hypertension1. Participant is claustrophobic and/or is known to
suffer from moderate to severe anxiety during MRI
scans or similar procedures
2. Participant is obese and/or exceeds equipment
weight limit and/or circumference of the MRI portal
at time of screening
3. Participant has a metallic implant or another foreign
body which is not compatible with Magnetic
Resonance Imaging (MRI) (eg pacemakers,
defibrillator, vascular clips, drug pumps, implant(s),
or any other foreign bodies, extensive tattoo
covering a large part of their chest or head)
4. Female participants that are or may be pregnant
(confirmed or uncertain)
5. Received an MRI contrast agent within 72 h prior to
the MRI scan.
Record linkage with health administrative databases
Data collected of participants from the CAHHM will
be linked with health care administrative databases,
available in various provinces, for ascertainment of
cardiovascular-related health care services before and
after enrollment in the study as well as long-term
CVD outcomes. (Table 6) The International Classifi-
cation of Diseases (ICD) codes that will be used tomeasure various outcomes have been validated and
described in detail elsewhere [63]. Most provincial
health care administrative databases in Canada contain
a patient health card number as a unique identifier
that enables efficient deterministic data linkage of vari-
ous data sets, in this instance cohort data sets with
province- or region-specific administrative databases.
To protect patient privacy, the health card number
(HCN) in each database is typically scrambled creating
another unique anonymized identifier before the actual
data linkage. All participants were asked on the in-
formed consent if they were willing to provide HCN
as part of their parent cohort participation or as a
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pants 99.2 % have consented to provide their HCN).
Due to the federated nature of the health care system
in Canada, there is no single repository of administra-
tive databases. As a result, data linkage activities will
involve working with multiple data custodians and gov-
ernments across the country, and will require under-
standing of and compliance with each province’s health
information privacy legislation. The Alliance is plan-
ning to work with key data custodians such as the
Canadian Institute for Health Information (CIHI),
which collects hospital discharge abstracts for the
entire country except for Quebec, Statistics Canada
which houses the Canadian Mortality Database and the
Canadian Cancer Registry and various provincial health
services research units located across Canada including
the Institute for Clinical Evaluative Sciences (ICES) in
Ontario, Population Data BC, the Population Health
Research Unit, Dalhousie University, Régi de l’assur-
ance maladie Québec (RAMQ), etc. - each of which
hold administrative databases for their region/province.
Study outcomes
Primary outcomes
The primary outcomes include MI, Stroke, angioplasty,
percutaneous coronary interventions, coronary artery
bypass graft surgery, and other important chronic dis-
ease outcomes and death. Associations between context-
ual factors, CV risk factors and MRI markers will be
evaluated with these outcomes individually and as a
composite measure of CV events.
Secondary outcomes
Secondary outcomes for this project include:
– Congestive Heart Failure requiring hospitalization
New onset established risk factors using validated
alogrithms [63, 64]
– Incident diagnosis of diabetes by physician
– Incident diagnosis of hypertension by physician
– Incident diagnosis of significant cognitive
dysfunction (ie dementia) by physician.
Risk markers acquired through imaging and blood
samples
– Acquired parameters that are linked to the present
health status
– Candidate parameters for predicting cardiovascular
events which affect cardiac and cognitive
dysfunction. For further details, please refer to the
outcomes in the questionnaires and the MRI




The proportion of risk factors will be examined across
cohorts and overall. It is anticipated given the roughly
representative subcohorts that recruitment of the target
sample of 7000 will provide high power to compare the
relative frequency of risk factors comparing men and
women, participants across age strata and between non-
First Nations and First Nations' Participants.Risk factors to MRI findings
The prevalence of traditional CV risk factors will enable
determination of the relative risk of the risk factors on
subclinical MRI findings of RWMA, covert stroke and
liver adipose tissue. For example, if among 7000
CAHHM participants the frequency of hypertension is
25 % and the frequency of covert stroke is 6.6 %, we will
have a high power to detect a relative risk of hyperten-
sion on silent stroke of brain of 1.5 (95 % CI: 1.36 to
1.65).MRI to clinical events
Several MRI markers have been tested for their predict-
ive value versus CV events in several populations.
Given the planned 7000 subjects and a predicted inci-
dent CV 5 year event rate of 5.98 %[1], we have high
power (ie >90 %) to detect a hazard ratio (HR) of 2.6
among those with RWMA by MRI, high power to de-
tect a HR of 2.85 for stroke among those with silent
stroke by MRI. Further we will have approximately
80 % power to detect a 1.6-fold increase in new diabetes
in those with liver fat as estimated by MRI assuming an
incidence of new diabetes of approximately 10 %. Esti-
mations of power for sample sizes lower than this (ran-
ging from 5000 to the anticipated 7000 subjects) are
also shown in Table 7. Given the limited information re-
garding the predictive relationship between liver fat and
CVD, we identified only one published study conducted
in diabetics which suggested that liver fat was associ-
ated with a 1.9-fold increase in CV incidence [65], on
the other hand a study by Lazo et al. [66] reported that
NAFLD by ultrasound was not associated with excess in
all-cause or cardiovascular mortality in the NHANES
III study – general population. While our power is too
low to detect a HR of 1.9 between liver fat and CVD,
our multiethnic sample which includes 2 high risk
groups for visceral fat and especially liver fat and in
whom we are using a superior measure of liver fat
(which has greater precision as compared to ultra-
sound) [67] provides an opportunity for us to test the
association between liver fat and CVD events in other-
wise understudied populations.







7000/ (5920)1 6000 /(5120)1 5000/(4320)
Regional Wall Motion Abnormality 0.253 CVD 0.0598 2.60 >0.99/>0.99 >0.99/0.99 >0.99/>0.99
Silent Stroke 0.069 CVD 0.0598 2.85 >0.99 >0.99 >0.99
Liver Fata 0.063 T2DM 0.0974–0.1275 1.60 0.82 0.76 0.68
1 Assuming 20 % of the participants will have existing CVD the Number of Participants free of CVD and Cancer are shown in parenthesis; a (assuming a higher
proportion of First Nations participants are retained, relative to other groups)
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To investigate the association between risk factors and
subclinical MRI findings linear (visceral fat) and logistic
(RWMA, covert stroke, liver fat %) regression models
must be built separately for each MRI outcome used as
the dependent variable. Exposures such as age, sex, eth-
nicity, history of hypertension, diabetes, waist circumfer-
ence, apolipoprotein B/A ratio, current smoking,
physical activity, selected dietary (ie prudent diet score,
or ratio polyunsaturated fat/saturated fat), and measures
of cognitive function (ie when covert stroke is the out-
come) will first be tested univariately, and exposures
with a P < 0.10 will be taken forward and tested in multi-
variate regression models. If ethnicity is found to be an
independent predictor of an MRI outcome, it will be
tested with a composite CV risk score for an interaction
with the outcome.
After 5 years, when enough CVD events have been ac-
crued and ascertained through record linkage, the MRI
subclinical exposure of covert stroke, global or regional
ventricular function abnormalities, liver fat and visceral
fat will be tested versus CVD and death to determine
their predictive value of clinical events using the area
under the curve (C statistics), and net reclassification
improvement methods [68].
Contextual factors
Comparisons between urban and rural communities will
be conducted by linear mixed models for continuous
variables (ie BMI) and generalized linear mixed model
(GLMM) l for categorical variables (ie CVD events), in
each case treating community as the random effect.
Using a similar model, unadjusted correlations will be
estimated between the perceived (EPOCH-2) and object-
ive environmental measures (EPOCH-1) with the con-
tinuous or categorical outcomes. Multilevel modeling
will be used to evaluate the relation between exposures
at the community (FSA-level) and individual level with
outcomes for each individual. All models will examine
both perceived and objective environmental measures as
covariates adjusted for individual and community socio-
demographics. Interaction terms between urban and
rural and the perceived and objective environmental
measures will be investigated to determine if the con-
textual factors differ based on the type of community ieurban or rural. The contribution of variance in out-
comes explained by community risk factors as opposed
to the individual risk factors will be quantified using the
variance partition coefficient from each model. For the
continuous outcomes, linear multi-level modeling will
be used. For categorical outcomes (ie CVD), similar gen-
eralized linear multi-level models will be fit. Models will
be adjusted a priori for individual (age, sex, ethnicity,
and household income) and community variables.
Data management and data access
Participants provide information through self-reporting
(eg Health Services Research - HSR, Food Frequency
Questionnaire - FFQ) and interviewer administered tests
(eg cognitive function testing). Participants are invited by
email/mail and then directed to provide a brief informed
consent and complete 2 questionnaires on-line (HSR,
FFQ), once booked for an MRI visit and screened for
contraindication to MRI, they complete the remainder of
the assessment at the MRI site prior to or immediately
after their MRI. Physical measurements are taken by clinic
staff following a standardized protocol. Participants are
given a card or self–record their physical measurements,
highlighting any abnormal results. Data is then entered at
the clinical site or faxed in using Datafax. Quality control
notes are sent by the coordinating centre to the sites to
correct any missing or abnormal values.
Results reporting
CV risk score
All participants receive a CV risk score report after their
baseline assessment. The majority of participants receive
the non-lab INTERHEART risk score which includes
age, sex, family history, diabetes, hypertension, diet, ac-
tivity, smoking, second hand smoke and psychosocial
factors as previously described [69], and the First Na-
tions participants receive the lab-based risk score which
include apolipoproteins A and B and HbA1c..
Incidental findings (CIF)
Four core labs separately assess the Brain (Calgary or
Sunnybrook), Cardiac (Montreal Heart Institute), Ca-
rotid (Sunnybrook) and Abdomen (IUCPQ). The readers
follow a standardized reading protocol. Results are sent
to the central project office, where they are linked with
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are reported back to participants and their primary care
physicians if they consented to this on their informed
consent. (Fig. 1) The severe structural abnormalities are
shown in the Table 8. The letter emphasizes that this is
a research scan which should be followed up with a tar-
geted clinical scan organized by the primary care
physician.
Discussion
The Canadian Alliance for Healthy Hearts and Minds
seeks to understand the individual and contextual ori-
gins of CVD risk and will aid in the design of effective
policy and health interventions aimed at reducing popu-
lation levels of risk factors in Canada. CAHHM is a
unique cohort study which brings together participants’
enrolled in diverse cohorts from chronic disease focused
cohort studies, in addition to creation of a new First Na-
tions cohort.
First, CAHHM is unique as MRI is being used to iden-
tify subclinical disease, and is only one of two studies we
are aware of interrogating the brain, heart, carotid arter-
ies, and abdominal adiposity [70]. MRI represents an ad-
vantage over other imaging modalities as it is sensitiveFig. 1 MRI analysis and Clinical incidental Findings reportingto detect early, subclinical stages of disease on a system-
atic (blood) or regional (tissue) level. Availability of such
validated predictors may allow the development of more
effective early treatment and personalized primary pre-
vention strategies.
Second, we developed a detailed health services ques-
tionnaire which collects information on primary care
visits, counseling for health behaviors, screening for risk
factors, access to pharmacists, and visits to specialist
physicians. To our knowledge such a detailed collection
of cardiovascular-related health services information has
not been collected on such a large cross section of Cana-
dians and will provide valuable information to enable
creation of a Health Services “Report Card” for Cana-
dians in urban and rural/remote regions.
Third, our contextual assessment of communities across
Canada together with data from individuals included in
our partner cohorts will enable an investigation of the
“causes of the causes”, specifically the influence of context-
ual factors on CV risk factors. Two contextual factor as-
sessments are being undertaken. The modified EPOCH-1
is a standardized audit completed by research personnel at
the FSA level in all provinces of Canada and First Nations
reserves. This will provide information on the tobacco
Table 8 Severe Structural Abnormalities
Abnormality Criteria
Brain infarct Diameter ≥15 mm or cortical location
Myocardial
infarction
High signal in LGE images from extended MRI scan or
a segmental wall thickening of <10% (severe




Thoracic ˃50 mm (men), ˃45 mm (women)
Abdominal ˃45 mm (men), ˃40 (women)
Valvular
dysfunction
Moderate or severe, with LV dilatation or
dysfunction
Mass Positive criteria for malignancy or significant
compression or infiltration of vital structures
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and social connectedness. Their precise characterization in
communities across Canada will aid policy development
and inform population health interventions aimed at redu-
cing the risk for cardiac and cognitive dysfunction, and
other chronic diseases.
Finally, we strive to establish a diverse cohort. Specific
strategies we have adopted to enhance diverse ancestry
recruitment include: i. establishment of a new First Na-
tions cohort recruited from 10 communities across
Canada, ii. prioritization by ethnicity ie South Asian,
Chinese and African origin participants in the CPTP co-
horts’; and iii. targeted ethnic recruitment for South
Asians and Chinese origin people in Ontario.
Anticipated challenges
The CAHHM initiative is a massive undertaking to co-
ordinate the recruitment of new and existing cohort par-
ticipants from 7 existing cohorts and a new First
Nations cohort, facilitating MRI scanning in urban, rural
and remote regions, and conducting record linkage for
clinical events using Health Card Number, across prov-
inces, at multiple future time points. However, the study
is robustly underway due to the strong commitment of
interested participants, researchers, academic institu-
tions, and funding agencies.
Conclusions
The Canadian Alliance for Healthy Hearts and Minds
is a prospective cohort being established in Canada
with unique features including recruitment of individ-
uals from existing cohort studies, use of MRI of brain,
heart, carotid artery and abdomen to detect subclinical
abnormalities, detailed measurement of health services
utilization, and measurement of individual and commu-
nity level contextual factors. The information generated
in CAHHM will be used to develop community and in-
dividual level CV prevention strategies for the people
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